|
Dec 26
|
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
|
|
Dec 22
|
Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?
|
|
Dec 22
|
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
|
|
Nov 6
|
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
|
|
Aug 11
|
Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 11
|
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
|
|
Aug 10
|
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
|